After O
angiography O
by O
the O
venous O
route O
in O
patient O
n O
degree O
1 O
a O
biphasic O
reaction O
with O
an O
immediate O
reaction O
( O
dyspnea B
, O
loss B
of I
consciousness I
) O
and O
delayed O
macro B
- I
papular I
rash I
appeared O
, O
whilst O
patient O
n O
degree O
2 O
developed O
a O
generalised O
sensation O
of O
heat O
, O
persistent O
pain B
at O
the O
site O
of O
injection O
immediately O
and O
a O
generalised O
macro O
- O
papular O
reaction O
after O
24 O
hours O
. O

Nociceptin O
/ O
orphanin O
FQ O
and O
nocistatin O
on O
learning B
and I
memory I
impairment I
induced O
by O
scopolamine O
in O
mice O
. O

Phase O
2 O
trial O
of O
liposomal O
doxorubicin O
( O
40 O
mg O
/ O
m O
( O
2 O
) O
) O
in O
platinum O
/ O
paclitaxel O
- O
refractory O
ovarian B
and I
fallopian I
tube I
cancers I
and O
primary O
carcinoma B
of I
the I
peritoneum I
. O

BACKGROUND O
: O
Several O
studies O
have O
demonstrated O
liposomal O
doxorubicin O
( O
Doxil O
) O
to O
be O
an O
active O
antineoplastic O
agent O
in O
platinum O
- O
resistant O
ovarian B
cancer I
, O
with O
dose O
limiting O
toxicity B
of O
the O
standard O
dosing O
regimen O
( O
50 O
mg O
/ O
m O
( O
2 O
) O
q O
4 O
weeks O
) O
being O
severe O
erythrodysesthesia B
( O
" O
hand B
- I
foot I
syndrome I
" O
) O
and O
stomatitis B
. O

Six O
( O
12 O
% O
) O
and O
4 O
( O
8 O
% O
) O
patients O
experienced O
grade O
2 O
hand B
- I
foot I
syndrome I
and O
stomatitis B
, O
respectively O
( O
no O
episodes O
of O
grade O
3 O
) O
. O

CONCLUSION O
: O
This O
modified O
liposomal O
doxorubicin O
regimen O
results O
in O
less O
toxicity B
( O
stomatitis B
, O
hand B
- I
foot I
syndrome I
) O
than O
the O
standard O
FDA O
- O
approved O
dose O
schedule O
. O

A O
case O
of O
isotretinoin B
embryopathy I
with O
bilateral O
anotia B
and O
Taussig B
- I
Bing I
malformation I
. O

We O
report O
a O
newborn O
infant O
with O
multiple O
congenital O
anomalies O
( O
anotia B
and O
Taussig B
- I
Bing I
malformation I
) O
due O
to O
exposure O
to O
isotretinoin O
within O
the O
first O
trimester O
. O

Cocaine O
, O
ethanol O
, O
and O
cocaethylene O
cardiotoxity B
in O
an O
animal O
model O
of O
cocaine B
and I
ethanol I
abuse I
. O

Peak O
CE O
levels O
were O
associated O
with O
a O
45 O
% O
( O
SD O
+ O
/ O
- O
22 O
% O
, O
95 O
% O
CI O
= O
22 O
% O
to O
69 O
% O
) O
decrease B
in I
cardiac I
output I
( O
p O
< O
0 O
. O
05 O
) O
, O
a O
56 O
% O
( O
SD O
+ O
/ O
- O
23 O
% O
, O
95 O
% O
CI O
= O
32 O
% O
to O
80 O
% O
) O
decrease O
in O
dP O
/ O
dt O
( O
max O
) O
( O
p O
< O
. O
006 O
) O
, O
and O
a O
23 O
% O
( O
SD O
+ O
/ O
- O
15 O
% O
, O
95 O
% O
CI O
= O
7 O
% O
to O
49 O
% O
) O
decrease O
in O
SVO O
( O
2 O
) O
( O
p O
< O
0 O
. O
025 O
) O
. O

We O
describe O
a O
female O
patient O
with O
stable O
Parkinson B
' I
s I
disease I
who O
has O
shown O
a O
marked O
worsening O
of O
her O
motor O
functions O
following O
therapy O
of O
menopause O
related O
symptoms O
with O
veralipride O
, O
as O
well O
as O
the O
improvement O
of O
her O
symptoms O
back O
to O
baseline O
after O
discontinuation O
of O
the O
drug O
. O

Finally O
, O
resting O
and O
peak O
exercise O
abnormal B
left I
ventricular I
filling I
was O
detected O
in O
38 O
and O
35 O
% O
of O
patients O
as O
compared O
to O
19 O
and O
9 O
% O
of O
controls O
, O
respectively O
( O
p O
= O
0 O
. O
11 O
and O
0 O
. O
02 O
, O
respectively O
) O
. O

Phase O
2 O
early O
afterdepolarization O
as O
a O
trigger O
of O
polymorphic O
ventricular B
tachycardia I
in O
acquired O
long B
- I
QT I
syndrome I
: O
direct O
evidence O
from O
intracellular O
recordings O
in O
the O
intact O
left O
ventricular O
wall O
. O

METHODS O
: O
The O
combination O
of O
carboplatin O
( O
area O
under O
the O
concentration O
curve O
[ O
AUC O
] O
, O
5 O
) O
and O
liposomal O
doxorubicin O
( O
Doxil O
; O
starting O
dose O
, O
40 O
mg O
/ O
m O
( O
2 O
) O
) O
was O
administered O
intravenously O
every O
28 O
days O
to O
37 O
patients O
with O
recurrent O
squamous B
cell I
cervical I
carcinoma I
to O
determine O
antitumor O
activity O
and O
toxicity B
profile O
. O

Grade O
> O
or O
= O
2 O
nonhematologic O
toxicity B
included O
nausea B
in O
17 O
patients O
, O
emesis B
in O
14 O
patients O
, O
fatigue B
in O
9 O
patients O
, O
mucositis B
and O
/ O
or O
stomatitis B
in O
8 O
patients O
, O
constipation B
in O
6 O
patients O
, O
weight B
loss I
in O
5 O
patients O
, O
hand B
- I
foot I
syndrome I
in O
2 O
patients O
, O
and O
skin B
reactions I
in O
3 O
patients O
. O

Levodopa O
- O
induced O
ocular B
dyskinesias I
in O
Parkinson B
' I
s I
disease I
. O

The O
worst O
toxicities B
( O
% O
) O
observed O
were O
( O
CTC O
- O
NCI O
1 O
/ O
2 O
/ O
3 O
) O
: O
leukopenia B
45 O
. O
5 O
/ O
18 O
. O
2 O
/ O
6 O
. O
1 O
, O
thrombocytopenia B
33 O
. O
3 O
/ O
9 O
. O
1 O
/ O
6 O
. O
1 O
, O
vomitus B
24 O
. O
2 O
/ O
9 O
. O
1 O
/ O
0 O
, O
diarrhea B
36 O
. O
4 O
/ O
6 O
. O
1 O
/ O
3 O
. O
0 O
, O
stomatitis B
18 O
. O
2 O
/ O
9 O
. O
1 O
/ O
0 O
, O
hand B
- I
foot I
syndrome I
12 O
. O
1 O
/ O
0 O
/ O
0 O
. O

Two O
patients O
developed O
hemolytic B
- I
uremic I
syndrome I
( O
HUS B
) O
. O

All O
adenosine O
receptor O
agonists O
significantly O
decreased B
the I
locomotor I
activity I
in O
mice O
, O
and O
the O
effects O
were O
dose O
- O
dependent O
. O

Central B
nervous I
system I
toxicity I
following O
the O
administration O
of O
levobupivacaine O
for O
lumbar O
plexus O
block O
: O
A O
report O
of O
two O
cases O
. O

Plasma O
concentrations O
sufficient O
to O
result O
in O
central B
nervous I
system I
toxicity I
did O
not O
produce O
manifestations O
of O
cardiac B
toxicity I
in O
these O
2 O
patients O
. O

Vincristine O
was O
accidentally O
given O
intrathecally O
to O
a O
child O
with O
leukaemia B
, O
producing O
sensory B
and I
motor I
dysfunction I
followed O
by O
encephalopathy B
and O
death O
. O

Bilateral O
subthalamic O
nucleus O
stimulation O
for O
Parkinson B
' I
s I
disease I
. O

High O
frequency O
stimulation O
of O
the O
subthalamic O
nucleus O
( O
STN O
) O
is O
known O
to O
ameliorate O
the O
signs O
and O
symptoms O
of O
advanced O
Parkinson B
' I
s I
disease I
. O

METHOD O
: O
Twenty O
- O
three O
patients O
suffering O
from O
severe O
Parkinson B
' I
s I
disease I
( O
Stages O
III O
- O
V O
on O
Hoehn O
and O
Yahr O
scale O
) O
and O
, O
particularly O
bradykinesia B
, O
rigidity B
, O
and O
levodopa O
- O
induced O
dyskinesias B
underwent O
bilateral O
implantation O
of O
electrodes O
in O
the O
STN O
. O

Preoperative O
and O
postoperative O
assessments O
of O
these O
patients O
at O
1 O
, O
3 O
, O
6 O
and O
12 O
months O
follow O
- O
up O
, O
in O
" O
on O
" O
and O
" O
off O
" O
drug O
conditions O
, O
was O
carried O
out O
using O
Unified O
Parkinson B
' I
s I
Disease I
Rating O
Scale O
, O
Hoehn O
and O
Yahr O
staging O
, O
England O
activities O
of O
daily O
living O
score O
and O
video O
recordings O
. O

RESULTS O
: O
After O
one O
year O
of O
electrical O
stimulation O
of O
the O
STN O
, O
the O
patients O
' O
scores O
for O
activities O
of O
daily O
living O
and O
motor O
examination O
scores O
( O
Unified O
Parkinson B
' I
s I
Disease I
Rating O
Scale O
parts O
II O
and O
III O
) O
off O
medication O
improved O
by O
62 O
% O
and O
61 O
% O
respectively O
( O
p O
< O
0 O
. O
0005 O
) O
. O

CONCLUSION O
: O
Bilateral O
subthalamic O
nucleus O
stimulation O
is O
an O
effective O
treatment O
for O
advanced O
Parkinson B
' I
s I
disease I
. O

The O
reduction O
in O
the O
levodopa O
dose O
is O
useful O
in O
controlling O
drug B
- I
induced I
dyskinesias I
. O

Pure B
red I
cell I
aplasia I
, O
toxic B
dermatitis I
and O
lymphadenopathy B
in O
a O
patient O
taking O
diphenylhydantoin O
. O

A O
patient O
taking O
diphenylhydantoin O
for O
3 O
weeks O
developed O
a O
generalized O
skin B
rash I
, O
lymphadenopathy B
and O
pure B
red I
cell I
aplasia I
. O

Pure B
red I
cell I
aplasia I
associated O
with O
diphenylhydantoin O
medication O
has O
been O
reported O
in O
3 O
patients O
. O

In O
this O
patient O
the O
time O
relation O
between O
the O
ingestion O
of O
diphenylhydantoin O
and O
the O
occurrence O
of O
the O
skin B
rash I
, O
lymphadenopathy B
and O
pure B
red I
cell I
aplasia I
is O
very O
suggestive O
of O
a O
direct O
connection O
. O

Only O
one O
patient O
demonstrated O
a O
deterioration B
in I
visual I
field I
during O
the O
study O
period O
and O
discontinued O
treatment O
. O

Swallowing B
abnormalities I
and O
dyskinesia B
in O
Parkinson B
' I
s I
disease I
. O

Gastrointestinal B
abnormalities I
in O
Parkinson B
' I
s I
disease I
( O
PD B
) O
have O
been O
known O
for O
almost O
two O
centuries O
, O
but O
many O
aspects O
concerning O
their O
pathophysiology O
have O
not O
been O
completely O
clarified O
. O

Patients O
were O
asked O
about O
dysphagia B
and O
evaluated O
with O
the O
Unified O
Parkinson B
' I
s I
Disease I
Rating O
Scale O
Parts O
II O
and O
III O
and O
the O
Hoehn O
and O
Yahr O
scale O
. O

After O
180 O
min O
of O
temporary O
middle B
cerebral I
artery I
occlusion I
in O
spontaneously O
hypertensive B
rats O
, O
the O
effect O
of O
phenylephrine O
- O
induced O
hypertension B
on O
ischemic B
brain I
injury I
and O
blood O
- O
brain O
barrier O
permeability O
was O
determined O
. O

After O
admission O
, O
the O
patient O
received O
a O
continuous O
intravenous O
infusion O
of O
5 O
- O
FU O
( O
1000 O
mg O
/ O
day O
) O
, O
during O
which O
precordial B
pain I
with O
right B
bundle I
branch I
block I
occurred O
concomitantly O
with O
a O
high O
serum O
FBAL O
concentration O
of O
1955 O
ng O
/ O
ml O
. O

Hepatocellular B
carcinoma I
in O
Fanconi B
' I
s I
anemia I
treated O
with O
androgen O
and O
corticosteroid O
. O

The O
case O
of O
an O
11 O
- O
year O
- O
old O
boy O
is O
reported O
who O
was O
known O
to O
have O
Fanconi B
' I
s I
anemia I
for O
3 O
years O
and O
was O
treated O
with O
androgens O
, O
corticosteroids O
and O
transfusions O
. O

This O
case O
contributes O
to O
the O
previous O
observations O
that O
non O
- O
metastasizing O
hepatic B
neoplasms I
and O
peliosis B
can O
develop O
in O
patients O
with O
androgen O
- O
and O
corticosteroid O
- O
treated O
Fanconi B
' I
s I
anemia I
. O

Clinical O
evaluation O
of O
adverse O
effects O
during O
bepridil O
administration O
for O
atrial B
fibrillation I
and I
flutter I
. O

The O
dopamine O
agonist O
significantly O
impaired B
novel I
word I
learning I
compared O
to O
placebo O
. O

A O
47 O
- O
year O
- O
old O
woman O
presented O
for O
mastectomy O
and O
immediate O
latissimus O
dorsi O
flap O
reconstruction O
having O
been O
diagnosed O
with O
carcinoma B
of I
the I
breast I
6 O
months O
previously O
. O

Wilson B
' I
s I
disease I
is O
an O
autosomal O
recessive O
disorder O
of O
hepatic O
copper O
metabolism O
with O
consequent O
copper O
accumulation O
and O
toxicity B
in O
many O
tissues O
and O
consequent O
hepatic B
, I
neurologic I
and I
psychiatric I
disorders I
. O

We O
report O
a O
case O
of O
Wilson B
' I
s I
disease I
with O
chronic B
liver I
disease I
; O
moreover O
, O
in O
our O
patient O
, O
presenting O
also O
with O
high O
levels O
of O
state O
anxiety B
without O
depression B
, O
99mTc O
- O
ECD O
- O
SPECT O
showed O
cortical O
hypoperfusion O
in O
frontal O
lobes O
, O
more O
marked O
on O
the O
left O
frontal O
lobe O
. O

In O
our O
case O
the O
therapy O
with O
zinc O
acetate O
represented O
an O
effective O
treatment O
for O
a O
Wilson B
' I
s I
disease I
patient O
in O
which O
penicillamine O
- O
related O
side O
effects O
appeared O
. O

The O
safety O
of O
the O
zinc O
acetate O
allowed O
us O
to O
avoid O
other O
potentially O
toxic O
chelating O
drugs O
; O
this O
observation O
is O
in O
line O
with O
the O
growing O
evidence O
on O
the O
efficacy O
of O
the O
drug O
in O
the O
treatment O
of O
Wilson B
' I
s I
disease I
. O

Since O
most O
of O
Wilson B
' I
s I
disease I
penicillamine O
- O
treated O
patients O
do O
not O
seem O
to O
develop O
this O
skin B
lesion I
, O
it O
could O
be O
conceivable O
that O
a O
specific O
genetic O
factor O
is O
involved O
in O
drug O
response O
. O

Further O
studies O
are O
needed O
for O
a O
better O
clarification O
of O
Wilson B
' I
s I
disease I
therapy O
, O
and O
in O
particular O
to O
differentiate O
specific O
therapies O
for O
different O
Wilson B
' I
s I
disease I
phenotypes O
. O

Further O
studies O
are O
needed O
for O
a O
better O
clarification O
of O
Wilson B
' I
s I
disease I
therapy O
, O
and O
in O
particular O
to O
differentiate O
specific O
therapies O
for O
different O
Wilson B
' I
s I
disease I
phenotypes O
. O

A O
dramatic O
drop B
in I
blood I
pressure I
following O
prehospital O
GTN O
administration O
. O

Several O
minutes O
after O
the O
GTN O
the O
patient O
experienced O
a O
sudden O
drop B
in I
blood I
pressure I
and O
heart O
rate O
, O
this O
was O
rectified O
by O
atropine O
sulphate O
and O
a O
fluid O
challenge O
. O

In O
contrast O
, O
succimer O
treatment O
of O
rats O
not O
previously O
exposed O
to O
Pb O
produced O
lasting O
and O
pervasive O
cognitive B
and I
affective I
dysfunction I
comparable O
in O
magnitude O
to O
that O
produced O
by O
the O
higher O
Pb O
exposure O
regimen O
. O

We O
report O
a O
57 O
- O
year O
- O
old O
woman O
with O
end B
- I
stage I
renal I
disease I
receiving O
continuous O
ambulatory O
peritoneal O
dialysis O
( O
CAPD O
) O
, O
who O
developed O
slurred O
speech O
, O
tremor B
, O
bizarre O
behavior O
, O
progressive O
mental O
confusion B
, O
and O
2 O
episodes O
of O
generalized O
tonic B
- I
clonic I
seizure I
( O
GTCS B
) O
after O
5 O
doses O
of O
piperacillin O
/ O
tazobactam O
( O
2 O
g O
/ O
250 O
mg O
) O
were O
given O
for O
bronchiectasis B
with O
secondary B
infection I
. O

The O
selective O
deficit B
in I
fear I
recognition I
accuracy O
manifested O
by O
the O
RC O
group O
cannot O
be O
explained O
by O
the O
subacute O
effects O
of O
cocaine O
, O
or O
ecstasy O
, O
because O
recent O
and O
less O
recent O
users O
of O
these O
drugs O
within O
this O
group O
were O
similarly O
impaired O
. O

Topical O
0 O
. O
025 O
% O
capsaicin O
in O
chronic O
post B
- I
herpetic I
neuralgia I
: O
efficacy O
, O
predictors O
of O
response O
and O
long O
- O
term O
course O
. O

In O
order O
to O
evaluate O
the O
efficacy O
, O
time O
- O
course O
of O
action O
and O
predictors O
of O
response O
to O
topical O
capsaicin O
, O
39 O
patients O
with O
chronic O
post B
- I
herpetic I
neuralgia I
( O
PHN B
) O
, O
median O
duration O
24 O
months O
, O
were O
treated O
with O
0 O
. O
025 O
% O
capsaicin O
cream O
for O
8 O
weeks O
. O

Acute B
tubulo I
- I
interstitial I
nephritis I
( O
ATIN B
) O
is O
an O
important O
cause O
of O
acute B
renal I
failure I
resulting O
from O
a O
variety O
of O
insults O
, O
including O
immune O
complex O
- O
mediated O
tubulo B
- I
interstitial I
injury I
, O
but O
drugs O
such O
as O
non O
- O
steroidal O
anti O
- O
inflammatory O
drugs O
( O
NSAIDs O
) O
are O
a O
far O
more O
frequent O
cause O
. O

Elements O
common O
to O
these O
cases O
included O
a O
history O
of O
paranoid B
symptomatology O
and O
the O
concomitant O
occurrence O
of O
depressive B
and I
psychotic I
symptoms I
. O

Nonalcoholic B
fatty I
liver I
disease I
during O
valproate O
therapy O
. O

We O
report O
a O
case O
of O
nonalcoholic B
fatty I
liver I
disease I
( O
NAFLD B
) O
arising O
in O
a O
child O
who O
developed O
obesity B
during O
VPA O
treatment O
. O

Cocaine O
is O
a O
risk O
factor O
for O
both O
ischemic B
and I
haemorrhagic I
stroke I
. O

Late O
fulminant O
posterior B
reversible I
encephalopathy I
syndrome I
after O
liver O
transplant O
. O

CASE O
: O
We O
report O
the O
case O
of O
a O
46 O
- O
year O
- O
old O
woman O
who O
received O
a O
liver O
transplant O
in O
our O
center O
as O
treatment O
for O
alcoholic B
cirrhosis I
and O
in O
whom O
either O
a O
fulminant O
course O
of O
posterior B
leukoencephalopathy I
or O
posterior B
reversible I
encephalopathy I
syndrome I
developed O
110 O
days O
after O
transplant O
. O

CONCLUSIONS O
: O
Posterior B
reversible I
encephalopathy I
syndrome I
after O
liver O
transplant O
is O
rare O
. O

Binasal B
visual I
field I
defects I
are O
not O
specific O
to O
vigabatrin O
. O

Bilateral B
visual I
field I
abnormalities I
are O
common O
in O
the O
treated O
epilepsy B
population O
, O
irrespective O
of O
drug O
history O
. O

High O
- O
dose O
methotrexate O
( O
HD O
- O
MTX O
) O
is O
an O
important O
treatment O
for O
Burkitt B
lymphoma I
, O
but O
can O
cause O
hepatic B
and I
renal I
toxicity I
when O
its O
clearance O
is O
delayed O
. O

Neuropsychiatric O
behaviors O
in O
the O
MPTP O
marmoset O
model O
of O
Parkinson B
' I
s I
disease I
. O

OBJECTIVES O
: O
Neuropsychiatric O
symptoms O
are O
increasingly O
recognised O
as O
a O
significant O
problem O
in O
patients O
with O
Parkinson B
' I
s I
disease I
( O
PD B
) O
. O

Here O
we O
compare O
the O
time O
course O
of O
levodopa O
- O
induced O
motor O
fluctuations O
and O
neuropsychiatric B
- I
like I
behaviors I
to O
determine O
the O
relationship O
between O
duration O
of O
treatment O
and O
onset O
of O
symptoms O
. O

Animals O
were O
evaluated O
for O
parkinsonian B
disability I
, O
dyskinesia B
and O
on O
- O
time O
( O
motor O
fluctuations O
) O
and O
neuropsychiatric B
- I
like I
behaviors I
on O
Day O
0 O
( O
prior O
to O
levodopa O
) O
and O
on O
Days O
1 O
, O
7 O
, O
13 O
, O
27 O
and O
30 O
of O
treatment O
using O
post O
hoc O
DVD O
analysis O
by O
a O
trained O
rater O
, O
blind O
to O
the O
treatment O
day O
. O

RESULTS O
: O
The O
neuropsychiatric B
- I
like I
behavior I
rating O
scale O
demonstrated O
high O
interrater O
reliability O
between O
three O
trained O
raters O
of O
differing O
professional O
backgrounds O
. O

In O
contrast O
, O
levodopa O
- O
induced O
neuropsychiatric B
- I
like I
behaviors I
were O
present O
on O
Day O
1 O
of O
levodopa O
treatment O
and O
their O
severity O
did O
not O
correlate O
with O
duration O
of O
treatment O
. O

Cerebellar O
sensory O
processing O
alterations O
impact O
motor O
cortical O
plasticity O
in O
Parkinson B
' I
s I
disease I
: O
clues O
from O
dyskinetic B
patients O
. O

The O
plasticity O
of O
primary O
motor O
cortex O
( O
M1 O
) O
in O
patients O
with O
Parkinson B
' I
s I
disease I
( O
PD B
) O
and O
levodopa O
- O
induced O
dyskinesias B
( O
LIDs B
) O
is O
severely O
impaired O
. O

Risk O
factors O
and O
predictors O
of O
levodopa O
- O
induced O
dyskinesia B
among O
multiethnic O
Malaysians O
with O
Parkinson B
' I
s I
disease I
. O

Chronic O
pulsatile O
levodopa O
therapy O
for O
Parkinson B
' I
s I
disease I
( O
PD B
) O
leads O
to O
the O
development O
of O
motor O
fluctuations O
and O
dyskinesia B
. O

Busulfan O
levels O
were O
measured O
by O
a O
gas O
chromatographic O
- O
mass O
spectrometry O
assay O
in O
the O
plasma O
and O
cerebrospinal O
fluid O
of O
9 O
children O
without O
central B
nervous I
system I
disease I
under O
600 O
mg O
/ O
m2 O
busulfan O
with O
clonazepam O
: O
busulfan O
cerebrospinal O
fluid O
: O
plasma O
ratio O
was O
1 O
. O
39 O
. O

Basic O
and O
clinical O
research O
has O
demonstrated O
that O
dementia B
of O
sporadic O
Alzheimer B
' I
s I
disease I
( O
sAD O
) O
type O
is O
associated O
with O
dysfunction O
of O
the O
insulin O
- O
receptor O
( O
IR O
) O
system O
followed O
by O
decreased O
glucose O
transport O
via O
glucose O
transporter O
GLUT4 O
and O
decreased O
glucose O
metabolism O
in O
brain O
cells O
. O

Association O
of O
common O
genetic O
variants O
of O
HOMER1 O
gene O
with O
levodopa O
adverse O
effects O
in O
Parkinson B
' I
s I
disease I
patients O
. O

Levodopa O
is O
the O
most O
effective O
symptomatic O
therapy O
for O
Parkinson B
' I
s I
disease I
, O
but O
its O
chronic O
use O
could O
lead O
to O
chronic O
adverse O
outcomes O
, O
such O
as O
motor O
fluctuations O
, O
dyskinesia B
and O
visual B
hallucinations I
. O

BACKGROUND O
: O
Ifosfamide O
is O
an O
alkylating O
agent O
useful O
in O
the O
treatment O
of O
a O
wide O
range O
of O
cancers B
including O
sarcomas B
, O
lymphoma B
, O
gynecologic B
and I
testicular I
cancers I
. O

All O
exhibited O
generalized O
tonic B
- I
clonic I
seizures I
within O
the O
first O
two O
wk O
after O
LT O
. O

She O
was O
admitted O
to O
our O
center O
for O
severe O
anemia B
due O
to O
menorrhagia B
and O
deterioration B
of I
renal I
function I
. O

METHODS O
: O
Seventy O
- O
five O
patients O
with O
non B
- I
Hodgkin I
lymphoma I
treated O
with O
epirubicin O
were O
studied O
. O

Paradoxical O
severe O
agitation B
induced O
by O
add O
- O
on O
high O
- O
doses O
quetiapine O
in O
schizo B
- I
affective I
disorder I
. O

We O
report O
the O
case O
of O
a O
35 O
- O
year O
- O
old O
patient O
suffering O
from O
schizo B
- I
affective I
disorder I
since O
the O
age O
of O
19 O
years O
, O
treated O
by O
a O
combination O
of O
first O
- O
generation O
antipsychotics O
, O
zuclopenthixol O
( O
100 O
mg O
/ O
day O
) O
and O
lithium O
( O
1200 O
mg O
/ O
day O
) O
( O
serum O
lithium O
= O
0 O
. O
85 O
mEq O
/ O
l O
) O
. O

A O
convulsive B
seizure B
was O
defined O
as O
a O
transient O
episode O
of O
disturbed O
brain O
function O
characterised O
by O
abnormal B
involuntary I
motor I
movements I
. O

Generalised B
and I
focal I
seizures I
were O
identified O
in O
68 O
and O
32 O
patients O
, O
respectively O
. O

Previous O
studies O
indicate O
that O
ecstasy O
users O
have O
marked O
and O
persistent O
neurocognitive O
and O
sleep B
- I
related I
impairments I
. O

Cerebellar B
and I
oculomotor I
dysfunction I
induced O
by O
rapid O
infusion O
of O
pethidine O
. O

Although O
the O
patient O
recovered O
, O
he O
experienced O
permanent O
vision B
and I
hearing I
loss I
, O
as O
well O
as O
end B
- I
stage I
renal I
disease I
. O

RESULTS O
: O
We O
evaluated O
143 O
patients O
who O
received O
single O
- O
agent O
cisplatin O
; O
97 O
. O
2 O
% O
of O
patients O
had O
head B
and I
neck I
cancer I
as O
their O
primary O
malignancy B
. O

Metformin O
protects O
against O
seizures B
, O
learning B
and I
memory I
impairments I
and O
oxidative O
damage O
induced O
by O
pentylenetetrazole O
- O
induced O
kindling O
in O
mice O
. O

Two O
cases O
of O
propylthiouracil O
- O
associated O
acute O
hepatitis B
, O
one O
case O
of O
fatal O
methimazole O
- O
associated O
hepatocellular B
necrosis I
and O
one O
case O
of O
propylthiouracil O
- O
associated O
lupus B
- I
like I
syndrome I
are O
described O
. O

Neuroleptic B
malignant I
syndrome I
induced O
by O
combination O
therapy O
with O
tetrabenazine O
and O
tiapride O
in O
a O
Japanese O
patient O
with O
Huntington B
' I
s I
disease I
at O
the O
terminal O
stage O
of O
recurrent O
breast B
cancer I
. O

We O
herein O
describe O
the O
case O
of O
an O
81 O
- O
year O
- O
old O
Japanese O
woman O
with O
neuroleptic B
malignant I
syndrome I
that O
occurred O
36 O
days O
after O
the O
initiation O
of O
combination O
therapy O
with O
tiapride O
( O
75 O
mg O
/ O
day O
) O
and O
tetrabenazine O
( O
12 O
. O
5 O
mg O
/ O
day O
) O
for O
Huntington B
' I
s I
disease I
. O

Rhabdomyolysis B
in O
a O
hepatitis B
C I
virus I
infected I
patient O
treated O
with O
telaprevir O
and O
simvastatin O
. O

A O
46 O
- O
year O
old O
man O
with O
a O
chronic O
hepatitis B
C I
virus I
infection I
received O
triple O
therapy O
with O
ribavirin O
, O
pegylated O
interferon O
and O
telaprevir O
. O

We O
report O
a O
case O
about O
a O
female O
with O
essential O
hypertension B
on O
drug O
treatment O
with O
amlodipine O
developed O
loss B
of I
taste I
sensation I
. O

Associations O
of O
Ozone O
and O
PM2 O
. O
5 O
Concentrations O
With O
Parkinson B
' I
s I
Disease I
Among O
Participants O
in O
the O
Agricultural O
Health O
Study O
. O

OBJECTIVE O
: O
This O
study O
describes O
associations O
of O
ozone O
and O
fine O
particulate O
matter O
with O
Parkinson B
' I
s I
disease I
observed O
among O
farmers O
in O
North O
Carolina O
and O
Iowa O
. O

METHODS O
: O
We O
used O
logistic O
regression O
to O
determine O
the O
associations O
of O
these O
pollutants O
with O
self O
- O
reported O
, O
doctor O
- O
diagnosed O
Parkinson B
' I
s I
disease I
. O

RESULTS O
: O
We O
observed O
positive O
associations O
of O
Parkinson B
' I
s I
disease I
with O
ozone O
( O
odds O
ratio O
= O
1 O
. O
39 O
; O
95 O
% O
CI O
: O
0 O
. O
98 O
to O
1 O
. O
98 O
) O
and O
fine O
particulate O
matter O
( O
odds O
ratio O
= O
1 O
. O
34 O
; O
95 O
% O
CI O
: O
0 O
. O
93 O
to O
1 O
. O
93 O
) O
in O
North O
Carolina O
but O
not O
in O
Iowa O
. O

CONCLUSIONS O
: O
The O
plausibility O
of O
an O
effect O
of O
ambient O
concentrations O
of O
these O
pollutants O
on O
Parkinson B
' I
s I
disease I
risk O
is O
supported O
by O
experimental O
data O
demonstrating O
damage O
to O
dopaminergic O
neurons O
at O
relevant O
concentrations O
. O

These O
results O
demonstrated O
that O
PCE O
could O
induce O
dysplasia B
of I
fetal I
kidneys I
as O
well O
as O
glomerulosclerosis B
of O
adult O
offspring O
, O
and O
the O
low O
functional O
programming O
of O
renal O
AT2R O
might O
mediate O
the O
developmental O
origin O
of O
adult O
glomerulosclerosis B
. O

An O
80 O
year O
old O
diabetic B
male O
with O
evidence O
of O
peripheral B
and I
autonomic I
neuropathy I
was O
admitted O
with O
chest B
pain I
. O

During O
hypotension B
, O
the O
heart O
rate O
was O
stable O
without O
tachy B
- I
or I
bradycardia I
. O

Tonic B
- I
clonic I
seizures I
followed O
intravenous O
fluorescein O
injection O
for O
fundus O
angiography O
in O
a O
47 O
- O
year O
- O
old O
male O
. O

Because O
caffeine O
is O
an O
adenosine O
receptor O
antagonist O
, O
these O
results O
suggest O
that O
some O
panic B
disorder I
patients O
may O
have O
abnormalities B
in I
neuronal I
systems I
involving O
adenosine O
. O

An O
experimental O
model O
of O
focal B
segmental I
glomerular I
sclerosis I
( O
FSGS B
) O
was O
developed O
in O
rats O
by O
the O
combined O
administration O
of O
puromycin O
- O
aminonucleoside O
( O
AMNS O
) O
and O
protamine O
sulfate O
( O
PS O
) O
. O

Eighty O
patients O
who O
were O
to O
receive O
CYA O
50 O
mg O
/ O
kg O
/ O
d O
for O
four O
days O
as O
preparation O
for O
marrow O
grafting O
underwent O
a O
total O
of O
84 O
transplants O
for O
aplastic B
anemia I
, O
Wiskott B
- I
Aldrich I
syndrome I
, O
or O
severe B
combined I
immunodeficiency I
syndrome I
. O

Eighty O
patients O
who O
were O
to O
receive O
CYA O
50 O
mg O
/ O
kg O
/ O
d O
for O
four O
days O
as O
preparation O
for O
marrow O
grafting O
underwent O
a O
total O
of O
84 O
transplants O
for O
aplastic B
anemia I
, O
Wiskott B
- I
Aldrich I
syndrome I
, O
or O
severe B
combined I
immunodeficiency I
syndrome I
. O

Experimental O
studies O
in O
healthy O
human O
volunteers O
indicate O
aminoglycosides O
cause O
proximal O
tubular O
damage O
in O
most O
patients O
, O
but O
rarely O
, O
if O
ever O
, O
cause O
glomerular B
or I
tubular I
dysfunction I
. O

These O
results O
suggest O
that O
enhanced O
prostaglandin O
synthesis O
contributes O
to O
maintenance O
of O
renal O
function O
and O
morphological O
integrity O
, O
and O
that O
inhibition O
of O
prostaglandin O
synthesis O
may O
lead O
to O
pathological B
renal I
medullary I
lesions I
and O
deterioration B
of I
renal I
function I
. O

These O
results O
suggest O
that O
enhanced O
prostaglandin O
synthesis O
contributes O
to O
maintenance O
of O
renal O
function O
and O
morphological O
integrity O
, O
and O
that O
inhibition O
of O
prostaglandin O
synthesis O
may O
lead O
to O
pathological B
renal I
medullary I
lesions I
and O
deterioration B
of I
renal I
function I
. O

Recurrent O
subarachnoid B
hemorrhage I
associated O
with O
aminocaproic O
acid O
therapy O
and O
acute B
renal I
artery I
thrombosis I
. O

Serological O
evidence O
for O
Epstein B
Barr I
Virus I
infection I
was O
found O
in O
20 O
% O
of O
65 O
cyclosporine O
patients O
studied O
. O

In O
one O
recording O
a O
short O
period O
of O
regular O
sinus O
rhythm O
with O
intermittent O
2 O
/ O
1 O
S B
- I
A I
block I
was O
observed O
. O

The O
abnormal O
rhythm O
disappeared O
with O
the O
withdrawal O
of O
propranolol O
and O
when O
the O
drug O
was O
restarted O
a O
2 O
/ O
1 O
S B
- I
A I
block I
was O
seen O
. O

A O
case O
of O
nontraumatic O
dissecting B
aneurysm I
of O
the O
basilar O
artery O
in O
association O
with O
hypertension B
, O
smoke O
, O
and O
oral O
contraceptives O
is O
reported O
in O
a O
young O
female O
patient O
with O
a O
locked B
- I
in I
syndrome I
. O

Twenty O
carcinomas B
of I
the I
urinary I
bladder I
and O
one O
carcinoma B
of I
the I
prostate I
have O
been O
reported O
in O
association O
with O
its O
use O
. O

We O
evaluated O
the O
severity O
of O
motor B
disability I
and O
dyskinesias B
in O
seven O
levodopa O
- O
responsive O
patients O
with O
Parkinson B
' I
s I
disease I
after O
an O
acute O
challenge O
with O
the O
mixed O
dopamine O
agonist O
, O
apomorphine O
, O
before O
and O
after O
the O
administration O
of O
fluoxetine O
( O
20 O
mg O
twice O
per O
day O
) O
for O
11 O
+ O
/ O
- O
1 O
days O
. O

Only O
five O
patients O
experienced O
blood O
disorders O
, O
one O
of O
whom O
was O
exposed O
to O
TMP O
- O
SMZ O
; O
of O
seven O
with O
erythema B
multiforme I
and O
Stevens B
- I
Johnson I
syndrome I
, O
four O
were O
exposed O
to O
TMP O
- O
SMZ O
. O

The O
patient O
had O
no O
history O
of O
underlying O
ischaemic B
heart I
disease I
or O
Prinzmetal B
' I
s I
angina I
. O

As O
TNF O
and O
PAF O
are O
thought O
to O
be O
involved O
in O
the O
development O
of O
septic O
shock B
and O
adult B
respiratory I
distress I
syndrome I
, O
we O
hypothesize O
that O
high O
- O
dose O
Ara O
- O
C O
may O
be O
associated O
with O
cytokine O
release O
. O

Milk B
- I
alkali I
syndrome I
induced O
by O
1 O
, O
25 O
( O
OH O
) O
2D O
in O
a O
patient O
with O
hypoparathyroidism B
. O

Milk B
- I
alkali I
syndrome I
was O
first O
described O
70 O
years O
ago O
in O
the O
context O
of O
the O
treatment O
of O
peptic B
ulcer I
disease I
with O
large O
amounts O
of O
calcium O
and O
alkali O
. O

Although O
with O
current O
ulcer B
therapy O
( O
H O
- O
2 O
blockers O
, O
omeprazole O
, O
and O
sucralfate O
) O
, O
the O
frequency O
of O
milk B
- I
alkali I
syndrome I
has O
decreased O
significantly O
, O
the O
classic O
triad O
of O
hypercalcemia B
, O
alkalosis B
, O
and O
renal B
impairment I
remains O
the O
hallmark O
of O
the O
syndrome O
. O

Milk B
- I
alkali I
syndrome I
can O
present O
serious O
and O
occasionally O
life O
- O
threatening O
illness O
unless O
diagnosed O
and O
treated O
appropriately O
. O

This O
article O
presents O
a O
patient O
with O
hypoparathyroidism B
who O
was O
treated O
with O
calcium O
carbonate O
and O
calcitriol O
resulting O
in O
two O
admissions O
to O
the O
hospital O
for O
milk B
- I
alkali I
syndrome I
. O

This O
illustrates O
intravenous O
pamidronate O
as O
a O
valuable O
therapeutic O
tool O
when O
milk B
- I
alkali I
syndrome I
presents O
as O
hypercalcemic B
emergency I
. O

All O
women O
who O
had O
a O
recorded O
diagnosis O
of O
deep B
- I
vein I
thrombosis I
, O
venous B
thrombosis I
not O
otherwise O
specified O
, O
or O
pulmonary O
embolus O
during O
the O
study O
period O
, O
and O
who O
had O
been O
treated O
with O
an O
anticoagulant O
were O
identified O
as O
potential O
cases O
of O
VTE B
. O

Of O
the O
83 O
cases O
of O
VTE B
associated O
with O
use O
of O
combined O
OCs O
, O
43 O
were O
recorded O
as O
deep B
- I
vein I
thrombosis I
, O
35 O
as O
pulmonary O
thrombosis B
, O
and O
five O
as O
venous B
thrombosis I
not O
otherwise O
specified O
. O

Intraperitoneal O
injection O
of O
pilocarpine O
( O
400 O
mg O
/ O
kg O
) O
induced O
tonic B
and I
clonic I
seizure I
. O

A O
case O
of O
acute B
renal I
failure I
, O
due O
to O
occlusion B
of I
renal I
vessels I
in O
a O
patient O
with O
acute B
promyelocytic I
leukemia I
( O
APL B
) O
treated O
with O
all O
- O
trans O
- O
retinoic O
acid O
( O
ATRA O
) O
and O
tranexamic O
acid O
has O
been O
described O
recently O
. O

The O
baby O
died O
of O
cerebral B
and I
pulmonary I
hemorrhage I
. O

A O
41 O
- O
year O
- O
old O
woman O
with O
a O
strong O
history O
of O
postoperative B
nausea I
and I
vomiting I
presented O
for O
abdominal O
hysterectomy O
3 O
months O
after O
a O
previous O
anaesthetic O
where O
ondansetron O
prophylaxis O
had O
been O
used O
. O

The O
following O
factors O
appear O
to O
predispose O
to O
the O
development O
of O
this O
complication O
: O
abnormal O
cerebrospinal O
dynamics O
related O
to O
the O
presence O
of O
central B
nervous I
system I
leukemia I
, O
and O
epidural O
cerebrospinal O
leakage O
; O
elevated O
cerebrospinal O
fluid O
methothexate O
concentration O
related O
to O
abnormal O
cerebrospinal O
fluid O
dynamics O
and O
to O
inappropriately O
high O
methotrexate O
doses O
based O
on O
body O
surface O
area O
calculations O
in O
older O
children O
and O
adults O
; O
the O
presence O
of O
neurotoxic B
preservatives O
in O
commercially O
available O
methotrexate O
preparations O
and O
diluents O
; O
and O
the O
use O
of O

The O
incidence O
of O
neurotoxicity B
may O
be O
reduced O
by O
employing O
lower O
doses O
of O
methotrexate O
in O
the O
presence O
of O
central B
nervous I
system I
leukemia I
, O
in O
older O
children O
and O
adults O
, O
and O
in O
the O
presence O
of O
epidural O
leakage O
. O

A O
45 O
- O
year O
- O
old O
man O
, O
with O
a O
10 O
- O
year O
history O
of O
manic B
depression I
treated O
with O
lithium O
, O
was O
admitted O
with O
hyperosmolar B
, I
nonketotic I
coma I
. O

Recorded O
were O
dose O
- O
limiting O
adverse O
events O
: O
hyper B
- I
or I
hypotension I
( O
three O
) O
, O
severe O
abdominal B
pain I
( O
0 O
) O
, O
vomiting B
( O
0 O
) O
and O
retained B
placenta I
( O
four O
) O
. O

Images O
may O
need O
to O
be O
obtained O
using O
i O
. O
v O
. O
contrast O
material O
to O
enable O
diagnosis O
of O
ureteric B
stones I
or I
obstruction I
in O
patients O
with O
HIV B
infection I
who O
receive O
indinavir O
therapy O
. O

51 O
patients O
with O
medically O
refractory O
Parkinson B
' I
s I
disease I
underwent O
stereotactic O
posteromedial O
pallidotomy O
between O
August O
1993 O
and O
February O
1997 O
for O
treatment O
of O
bradykinesia B
, O
rigidity B
, O
and O
L O
- O
DOPA O
- O
induced O
dyskinesias B
. O

Clinical O
assessment O
as O
well O
as O
blinded O
ratings O
of O
Unified O
Parkinson B
' I
s I
Disease I
Rating O
Scale O
( O
UPDRS O
) O
scores O
were O
carried O
out O
pre O
- O
and O
postoperatively O
. O

Gamma O
Knife O
pallidotomy O
is O
as O
effective O
as O
radiofrequency O
pallidotomy O
in O
controlling O
certain O
of O
the O
symptoms O
of O
Parkinson B
' I
s I
disease I
. O

This O
response O
was O
significantly O
reduced O
by O
the O
intravenous O
( O
i O
. O
v O
. O
) O
injection O
of O
guanethidine O
( O
5 O
mg O
) O
, O
hexamethonium O
( O
10 O
mg O
) O
or O
phentolamine O
( O
5 O
mg O
) O
, O
and O
conversely O
, O
potentiated O
by O
i O
. O
v O
. O
desmethylimipramine O
( O
0 O
. O
3 O
mg O
) O
, O
while O
propranolol O
( O
0 O
. O
5 O
mg O
) O
i O
. O
v O
. O
selectively O
inhibited O
the O
enlargement B
of I
pulse I
pressure I
and O
the O
tachycardia B
following O
i O
. O
c O
. O
carbachol O
( O
1 O
mug O
) O
. O

She O
had O
defects O
in O
the O
supratentorial O
brain O
including O
the O
basal O
ganglia O
and O
the O
striatum O
( O
multicystic B
encephalomalacia I
) O
due O
to O
severe O
perinatal O
hypoxic B
- I
ischemic I
encephalopathy I
, O
which O
was O
considered O
to O
be O
a O
possible O
predisposing O
factor O
causing O
neuroleptic B
malignant I
syndrome I
. O

